期刊文献+

负载hTERT基因片段的慢病毒的包装及表达 被引量:1

Package and expression of lentivirus encoding hTERT gene
下载PDF
导出
摘要 目的构建编码人端粒酶逆转录酶(hTERT)的慢病毒载体,并测定其滴度,观察hTERT基因在体外的表达情况。方法采用RT-PCR获得hTERT基因片段,插入转移载体L166,用CaCl2法L166-hTERT、L205、L311共转染293T细胞包装慢病毒,测定病毒滴度,免疫细胞化学法检测慢病毒感染的293T细胞中hTERT的表达。结果测序结果显示成功构建了重组质粒L166-hTERT,测定未经浓缩的病毒滴度为5.25×106IU/mL,免疫细胞化学法检测到慢病毒感染的293T细胞中hTERT呈阳性表达。结论成功构建了负载hTERT基因片段的慢病毒,hTERT能在感染的293T细胞中高效表达,表达持续2个月以上。 Objective To construct a lentiviral vector encoding human telomerase reverse transcriptase(hTERT)genes. Methods A fragment of the hTERT gene was amplified by RT-PCR and was inserted into the plasmid L166. The three plasmids L166- hTERT, I205 and I311 co-transfected the virus packaging cell line 293T using the CaC12 method. Then the cell supernatant was harvested and virus titration was determined. Also the expression of hTERT in 293T cells infected by the lentivirus was determined by using the immunocytochemistry method. Results DNA sequencing demonstrated that the recombinant plasmid L166-hTERT was successfully constructed. The titration of the un-concentrated lentivirus was 5.25 ×10^6 IU/mL. hTERT polypeptid immunocytochemistry staining proved positive for the hTERT gene in infected 293T cells. Conclusion Lentivirus encoding hTERT was successfully packaged and hTERT could express in 293T cells for more than 2 months.
出处 《山东大学学报(医学版)》 CAS 北大核心 2008年第2期132-135,共4页 Journal of Shandong University:Health Sciences
基金 山东省科技发展计划项目(2004GG3202003)
关键词 人端粒酶逆转录酶 慢病毒载体 肿瘤疫苗 Human telomerase reverse transcriptase Lentivirus vector Tumor vaccine
  • 相关文献

参考文献2

二级参考文献28

  • 1Gu J, Kagawa S, Takakura M, et al. Tumor-specific trans gene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers[J]. Cancer Res, 2000, 60 (19):5359-5364.
  • 2Koga S, Hirohata S, Kondo Y,et al. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo[J]. Anticancer Res, 2001,21 (3B): 1937-1943.
  • 3Komata T, Kondo Y, Kanzawa T,et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter [J].Cancer Res, 2001,61 (15) :5796-802.
  • 4Gu J, Andreeff M, Roth JA, et al. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity[J]. Gene Ther, 2002,9 ( 1 ): 30-37.
  • 5Koga S, Hirohata S, Kondo Y,et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter[J]. Hum Gene Ther, 2000,11 (10): 1397-1406.
  • 6Komata T, Kondo Y, Kanzawa T,et al. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells [J]. Hum Gene Ther, 2002, 13 (9):1015-1025.
  • 7Komata T, Koga S, Hirohata S, et al. A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter [J ]. Int J Oncol, 2001, 19 ( 5 ):1015-1020.
  • 8Lin T, Huang X, Gu J, et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cell[J]. Oncogene,2002,21 (52): 8020-8028.
  • 9Kirch HC,Ruschen S, Brockmann D, et al. Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300/CBP/HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression system [J]. Oncogene, 2002, 21 ( 52 ):7991-8000.
  • 10Liu J, Zou WG, Lang MF. Cancep-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter[J]. Int J Oncol, 2002,21 (3) :661-666.?A?A

共引文献3

同被引文献11

  • 1Dresch C. Edelmann S L. Marconi P, et al. Lentiviral mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo[J]. J Immunol. 2008.181(7) :4195-4506.
  • 2Coutant F. Frenkiel M P, Despres P. et al. Protective antiviral immunity conferred by a nonintegrative lentiviral vector based vaccine[J].PLoS One, 2008.3( 12):e3973.
  • 3Stripecke R. Lentiviral 3ector mediated genetic programming of mousc and human dendritic cells[J].Methods Mol Biol, 2009. 506:139-158.
  • 4Han S. Chang L J. Immunity of lentiviral vector modified dendritic cells[J]. Methods Mol Biol, 2009. 542:215-559.
  • 5Arce F, Rowe H M. Chain B, et al.Lentiviral vectors transduce proliferating dendrilic cell precursors leading to persistent antigen presentation and immunization[J].Mol Ther, 2009, 17(9) : 1613-1650.
  • 6Kokhaei P, Palma M, Hansson L, et al. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells[J]. Exp Hematol, 2007, 35(2):297-304.
  • 7Aloysius M M, Mc Kechnic A J, Robins R A. et al. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class Ⅰ and Ⅱ ) peptide pulsed DCs[J]. J Transl Med. 2009. 7:18.
  • 8Chen L, Tang X D, Yu S T, et al. Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirusin mice[J].J Pathol, 2009, 217(5):685-692.
  • 9Seggewiss R, Dunbar C E.A new direction forgcne therapy:intrathymic T cell--specific lentiviral gene transfer[J]. J Clin Invest. 2005, 115(8) :2061-2067.
  • 10Doi K, Hargitai J, Kong J. et al. l,entiviral transduction of green fluorescent protein in retinal epithelium: evidence of rejection[J].Vision Res, 2002. 42(1):551-558.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部